文献速递结核与非结核分枝杆菌

预防耐多药结核病:新时代的黎明

Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era.
PubMed 文献 · Clin Infect Dis · 2026-01-01

耐多药结核病(MDR-TB)仍是全球健康威胁,占抗菌药物耐药相关死亡的四分之一。近期两项随机试验首次提供证据:MDR-TB家庭接触者每日使用左氧氟沙星6个月预防结核病安全有效。世界卫生组织据此更新指南,强烈推荐MDR-TB暴露接触者使用左氧氟沙星6个月。

要点

  • MDR-TB家庭接触者每日左氧氟沙星6个月可安全有效预防结核病。
  • WHO更新指南,强烈推荐MDR-TB暴露接触者使用左氧氟沙星6个月。
  • 更短疗程的新方案正在研发中,若证实安全有效将开启治疗新时代。

核心结论

  • 每日左氧氟沙星6个月可安全有效地预防MDR-TB暴露家庭接触者进展为结核病。
  • WHO基于两项随机试验更新指南,强烈推荐MDR-TB暴露接触者使用左氧氟沙星6个月。

研究设计与样本

  • 两项近期完成的随机试验,评估MDR-TB家庭接触者每日左氧氟沙星6个月的预防效果。

主要发现

  • 两项随机试验首次提供证据,表明MDR-TB家庭接触者每日左氧氟沙星6个月预防结核病安全有效。

关键数值与推荐

  • WHO指南强烈推荐MDR-TB暴露接触者使用左氧氟沙星6个月进行结核病预防治疗。

临床怎么用

  • 对MDR-TB家庭接触者应考虑每日左氧氟沙星6个月预防结核病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multidrug-resistant tuberculosis (MDR-TB) remains a global health threat and accounts for a quarter of deaths due to antimicrobial resistance. Individuals infected with MDR-TB are at risk of progressing to TB disease. Treatment of drug-resistant TB infection to prevent progression to disease and avert the associated morbidity and mortality is a global priority. Randomized evidence to inform TB preventive treatment (TPT) guidelines has been lacking. Two recently completed trials provide the first randomized evidence that treatment of household contacts exposed to people with MDR-TB with daily levofloxacin for 6 months is safe and efficacious in preventing TB. Based on these results, the World Health Organization updated its TPT guidelines to make a strong recommendation for use of levofloxacin for 6 months in MDR-TB exposed contacts. Novel, shorter regimens in development will usher in a new era for the treatment of MDR-TB infection if shown to be safe and efficacious.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Churchyard GJ, Swindells S, Gupta A, et al. Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era. Clin Infect Dis. 2026. PMID: 40795178. doi:10.1093/cid/ciaf426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。